Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TransEnterix Names New CFO, Reports Negative Q2 Earnings Amid Challenging Times

Executive Summary

TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.

You may also be interested in...



SAGES 2019: Spotlighting Competitive Robotic Systems And Procedures

Surgical robotics giant Intuitive Surgical will soon face competition from Medtronic and Verb Surgical. With the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) annual meeting on the way in Baltimore, MD this week, Wells Fargo analyst Larry Biegelsen offers an outlook on competitive robotic systems and the rising popularity by surgeons to use robotics systems in hernia, bariatric, cholecystectomy and colorectal procedures.

Philips Announces CEO Succession In Midst Of Massive Recall

Philips CEO Frans van Houten will leave the company in October amid a massive recall of ventilators and related products. Roy Jakobs will succeed van Houten as CEO and president effective 15 October, Philips said.

De Oro Devices’ Nex(t)Stride To Help Freezing Gait Is Expand Into Other Diseases, Add Software

De Oro Devices’ plans to add more indications for its portable device for freezing gait associated with Parkinson’s disease. In 2023, the company hopes to address , multiple sclerosis, stroke and cerebral palsy, and add mobility-gait software.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT142585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel